Biotechnology company Zion Pharma Limited Tuesday announced the start of its Phase 1 study of its lead programme ZN-A-1041 at several sites across the US, including the Dana Farber Cancer Institute and the Duke Cancer Institute, in the US.
The Chinese company added that ZN-A-1041 is a best-in-class, small molecule tyrosine kinase receptor inhibitor targeting HER2. It is being developed to address the unmet medical need associated with brain metastases accompanying HER2+ advanced breast cancer.
Following dosing of the first patient in our Phase 1 study, Zion becomes a clinical stage company within 30 months of forming the company, stated Zack Cheng, PhD, chairman, CEO and co-founder.
Upon completion of USD20m Series A follow-on financing, the company has sufficient funding for the next two years and expects to complete the ZN-A-1041 Phase 1 study in the US and China and advance other programmes into IND-enabling studies, said Cheng.
Concurrently, the company has named Wendy Li, MD as chief medical officer. Previously, Dr Li was part of oncology clinical development at Genentech, Sanofi and Pfizer as well as prior VP/CMO with Sihuan Pharma/Xuanzhu Shandong and CMO at Exuma Biotech.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer